Oligonucleotides Products & Reviews

CPG for the incorporation of a 2'-fluoro modified nucleobase at the 3' end of an oligonucleotide

CPG for the incorporation of a 2'-O-methyl modified ribo- nucleobase at the 3' end of an oligonucleotide.

CPG for the incorporation of an (otherwise unmodified) reverse (5' to 3') nucleobase at the 3' end of an oligonucleotide.

CPG used to incorporate the cyanine-5 dye moiety onto the 3'-end of an oligonucleotide.

A phosphoramidite used for 5'-CAL Fluor Red 610 labelling of oligonucleotides.

CPG for the incorporation of a 2'-O-methyl modified ribo-A nucleobase at the 3' end of an oligonucleotide.

CPG for incorporation of a 2'-O-methyl modified ribo-C nucleobase at the 3' end of an oligonucleotide.

CPG for incorporation of unmodified ribo-G at 3' end of an oligonucleotide.

CPG for incorporation of a 2'-O-methyl modified U nucleobase at the 3' end of an oligonucleotide.

CPG for incorporation of GalNAc at 3' end of an oligonucleotide, with a dR spacer.

CPG for the incorporation of cholesterol at 3' end of an oligonucleotide, with a dR spacer.

Primer and probe pools for the U.S. CDC and and Charité tests.

The Odyssey® Infrared EMSA Kit coupled with IRDye® 700 EMSA oligonucleotides is an excellent alternative method to radioisotopic and chemiluminescent detection methods for EMSA analysis and visualization. Using IRDye EMSA reagents, assays can be completed in less than two hours with no gel transfer or film exposure.

A DNA oligonucleotide end-labeled with IRDye 700 infrared dye is a good substrate for protein binding. Using the Odyssey Infrared Imaging System, IRDye infrared dye labeled DNA detection is linear within a 50-fold dilution range from 9.1 fmol to 0.18 fmol.

Our Metabolite Identification service employs HRMS /LC-MS/MS to decode degradation pathways of antisense oligonucleotides (ASOs), siRNAs, and modified variants, identifying chain-shortened metabolites (5’/3’ cleavage), phosphorothioate changes (desulfurization, inversion) and base/nucleotide alterations (deamination/depurination). Through plasma/tissue/cell analysis, we reveal metabolic stability, biodistribution, and exonucle…

High-quality deoxynucleotide triphosphates (dNTPs) are critical for the success of many key procedures such as cDNA synthesis, sequencing and labeling.   Promega dNTPs have greater than 99% triphosphate content and are provided at a concentration of 100mM in water at pH 7.5. dNTPs Features & Benefits:   Dependable - PCR-tested deoxynucleotides ensure optimal performance with all Promega amplification enzyme…

Creative Biolabs delivers an end-to-end CAR-T development pathway—from target/scFv discovery, CAR design and vectoring, and cell engineering to in-vitro/in-vivo efficacy, IND authoring, and manufacturing support. Modular and GMP-aligned, the platform spans autologous and allogeneic routes (incl. TRAC/Cas9 and mRNA) to de-risk translation for hematologic and solid tumor programs.

End‑to‑end TCR‑like antibody services targeting peptide–MHC complexes—covering immunogen design, pMHC screening, affinity maturation, developability optimization, and functional validation—with output as IgG, bispecifics, or CAR constructs to access intracellular‑derived antigens.

End‑to‑end solid‑tumor CAR‑T development—from antigen/scFv discovery and CAR optimization to cell engineering, in‑vitro/in‑vivo efficacy, and IND support. Incorporates dual/logic‑gated and armored CARs, plus trafficking and persistence enhancements to overcome the tumor microenvironment and improve safety and translation.

Tailored formulation and conjugation for nucleic acids and biologics, covering LNPs and alternative carriers, ligand-directed strategies (e.g., GalNAc), and full characterization and process development to enhance stability, targeting, and potency with documentation for scale-up and regulatory needs.

Custom DNA/RNA oligonucleotide synthesis with broad modification choices (PS, 2′-OMe, 2′-F, LNA, GalNAc, dyes/biotin), multiple scales and purifications, and analytical QC. Includes design consultation and documentation to support research, translational studies, and conjugation-ready formats.

Integrated ASO development from sequence design and chemistry selection to preclinical PK/PD, safety, delivery (e.g., GalNAc), and CMC—supporting gapmer and steric-blocker approaches to advance programs efficiently toward IND.

End‑to‑end allogeneic cell therapy development—covering donor strategy, multiplex genome editing for safety/immune evasion, scalable manufacturing and comparability, and IND/CMC support—across CAR‑T/CAR‑NK and other donor‑derived modalities to enable off‑the‑shelf access.

Configurable TIL therapy development spanning tumor processing, TIL isolation/rapid expansion, functional and phenotypic qualification, and release criteria—paired with manufacturing‑aligned process development and IND documentation to de‑risk scale‑up for solid‑tumor programs.

Comprehensive circRNA services including design, circularization (e.g., ribozyme/intron-mediated), purification, and analytics to deliver stable, translation-competent RNA with improved durability—supported by process development for research and translational programs.